Last reviewed · How we verify
NCT07096947: MTEGC
A Multifactor Prediction Model for Non-curative Outcomes in Mixed-type Early Gastric Cancer
trial in Mixed-type Early Gastric Cancer in 421 participants. Completed in 15 June 2025.
31 December 2022
Quick facts
| Lead sponsor | The First Affiliated Hospital of Nanchang University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 421 |
| Start date | 18 January 2017 |
| Primary completion | 31 December 2022 |
| Estimated completion | 15 June 2025 |
| Sites | 1 location across China |
Conditions studied
- Mixed-type Early Gastric Cancer — all drugs for Mixed-type Early Gastric Cancer →
Sponsor
The First Affiliated Hospital of Nanchang University
Who can join
Adults 18 to 85, any sex, with Mixed-type Early Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this dual-center study is to identify the most valuable predictive factors (MVPs) for non-curable mixed-type early gastric cancer (NC-MTEGC) and develop a nomogram scoring model to assist surgeons in formulating precise postoperative combined radiochemotherapy strategies in patients with mixed-type early gastric cancer (MTEGC) who have undergone radical surgical resection. The main question it aims to answer is: What are the most valuable predictive factors for NC-MTEGC, and can a nomogram scoring model developed based on these factors effectively assist in formulating precise postoperative combined radiochemotherapy strategies? Patients with MTEGC who have undergone radical surgical resection (including 160 in the training group, 151 in the internal validation set from the First Affiliated Hospital of Nanchang University, and 110 in the external test cohort from the Second Affiliated Hospital of Nanchang University) will be included in the study. The Least Absolute Shrinkage and Selection Operator (LASSO) algorithm will be used to assess key predictive indicators, a nomogram prediction model will be developed based on logistic regression, and an NC-MTEGC risk score model will be constructed. Meanwhile, the model's discriminatory ability, calibration, and clinical utility will be comprehensively validated across the three cohorts, with follow-up for relevant conditions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07096947
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other The First Affiliated Hospital of Nanchang University trials
Trials by the same sponsor.
- NCT06639516 — Therapeutic Effect of Bifidobacterium Longum in Patients with Acute Pancreatitis: a Randomized, Double-Blind, Placebo-Co · NA · not yet recruiting
- NCT07136961 — Efficacy and Safety of Robotic-assisted Bronchoscopy Combined With the ICNVA Strategy in Biopsy of Peripheral Pulmonary · NA · active not recruiting
- NCT06999031 — A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma · EARLY_PHASE1 · recruiting
- NCT06751966 — Neoantigen-based Peptide Vaccine and Conventional Third-line Therapy for CRC Progressed After Second-line Treatment · NA · recruiting
- NCT06752057 — Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07096947 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Nanchang University
- Last refreshed: 31 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07096947.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing